Company Overview of Boston Biomedical, Inc.
Boston Biomedical, Inc., a biotechnology company, develops a pipeline of cancer cell stemness inhibitors that target cancer stem cells (CSCs). It offers BBI608, a CSC inhibitor in preparation for Phase III trials for patients with colorectal cancer in North America, as well as various Phase Ib and Phase II trials for various solid tumors; and BBI503, a cancer stemness kinase inhibitor in multi-center Phase I trials for patients with various solid tumors in North America. The company also provides ARQ 501, an activated checkpoint therapy (ACTSM)-based small molecule that kills cancer cells through E2F1-mediated DNA damage checkpoint pathway; ARQ 197, a non-ATP competitive selective c-Met inhi...
333 Providence Highway
Norwood, MA 02062
Founded in 2006
Key Executives for Boston Biomedical, Inc.
Chief Operating Officer and Vice President
Chief Commercial Officer and Executive Vice President
Vice President of Product Development & Business Affairs
Compensation as of Fiscal Year 2013.
Boston Biomedical, Inc. Key Developments
Boston Biomedical, Inc. and Boston Biomedical Pharma Inc. Appoint Patricia S. Andrews as Executive Vice President and Chief Commercial Officer
Nov 14 13
Boston Biomedical, Inc. and Boston Biomedical Pharma Inc., collectively "Boston Biomedical", announced that it has appointed Patricia S. Andrews as Executive Vice President and Chief Commercial Officer as it begins strategic planning and preparations for the commercialization of its cancer stem cell inhibitors with its lead asset, BBI608, currently in a global Phase 3 clinical trial for metastatic colorectal cancer. Ms. Andrews most recently served as Executive Vice President and Chief Commercial Officer at Incyte Corporation.
Boston Biomedical, Inc. Opens of its Cambridge Headquarters
Jul 12 13
Boston Biomedical, Inc. announced the relocation of its headquarters to Cambridge, Massachusetts. The new, 64,000-square-foot facility is located at 640 Memorial Drive, situated at the epicenter of the region's life science and technology clusters. With a new and support from DSP, Boston Biomedical aims to continue to leverage its scientific excellence and leadership in order to advance the development of novel cancer therapeutics.
Boston Biomedical, Inc. Moves to New Office at Cambridge
Feb 7 13
Boston Biomedical, Inc. announced that it is moving the company into the much bigger offices in Cambridge, Mass. and plans to have 100 employees by the end of the year. On January 8, 2013, the company plans to open its new headquarters at 640 Memorial Drive. The 64,000-square-foot site will replace the company's 10,000-square-foot headquarters in Norwood, Mass. The new location, directly across from the Boston University Bridge in the Cambridge port section of the city, has previously housed innovative companies and institutions including Ford, Polaroid and MIT. The new center will serve as the Global Oncology Center for DSP, in much the same way that Millennium is the global oncology center for Takeda Pharmaceuticals, the company announced that it will operate independently, with DSP as its sole financier. The company announced that most of the 50 or so employees he plans to hire in the next year will be researchers.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|